Harry Erba
MD, PhD
Professor of Medicine, Director Leukemia Program
👥Biography 个人简介
Harry Erba has led multiple clinical trials evaluating gemtuzumab ozogamicin in AML, contributing to its re-approval after initial regulatory withdrawal. His research has focused on optimal dosing and patient selection for GO-based regimens. He has also contributed to defining the role of measurable residual disease (MRD) in AML treatment decisions and is active in ECOG-ACRIN cooperative group leukemia trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Harry Erba 的研究动态
Follow Harry Erba's research updates
留下邮箱，当我们发布与 Harry Erba（Duke University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment